Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 35 Issue 3, March 2017

"Targeting RNA", inspired by the focus on RNA-based therapies. Image credit: Suzanne Harris

Editorial

  • RNA-based therapeutics are poised to become successful commercial products, but wide adoption across the biopharmaceutical industry will likely take a few more years.

    Editorial

    Advertisement

Top of page ⤴

News

Top of page ⤴

Podcast

Top of page ⤴

News

Top of page ⤴

News Feature

  • After years under the radar, RNA vaccines are finally emerging as immunotherapies to combat pandemics and cancer. But as Laura DeFrancesco reports, clinical validation remains elusive.

    • Laura DeFrancesco
    News Feature
  • The long, tortuous race to market a therapeutic based on RNA interference (RNAi) may be nearing its end. Ken Garber reports.

    • Ken Garber
    News Feature
Top of page ⤴

Data Page

Top of page ⤴

Correspondence

Top of page ⤴

Patents

Top of page ⤴

News & Views

Top of page ⤴

Perspective

Top of page ⤴

Review Article

Top of page ⤴

Article

Top of page ⤴

Letter

Top of page ⤴

Careers and Recruitment

Top of page ⤴

In This Issue

Top of page ⤴

Search

Quick links